CORRECTION, 5/29/13, 6:55 p.m. EDT: The names of Osler partner Peter Glossop and associate Amanda Heale were misspelled in the original version of this article. The names have been corrected in the tenth paragraph. We regret the error.
After months of eyeing possible acquisition targets, Canada’s Valeant Pharmaceuticals International decided to narrow its sights on Bausch & Lomb.
Laval, Quebecbased Valeant said Monday that it has agreed to acquire the contact lens maker in a cash deal worth $8.7 billion. The transaction’s terms call for Valeant to pay $4.5 billion to a group of Bausch & Lomb investors led by private equity firm Warburg Pincus, with the remaining $4.2 billion earmarked to pay off the target’s debt.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
